Literature DB >> 35273409

Course and Predictors of Visual Outcome of Idiopathic Intracranial Hypertension.

Raed Behbehani1, Abdullah Ali1, Ashraf Al-Moosa1.   

Abstract

Idiopathic intracranial hypertension (IIH) is a clinical syndrome characterised by headache and papilloedema that can lead to significant visual morbidity. There are few studies in the literature about the visual outcome of IIH. We have reviewed the record of 76 patients with IIH according to the modified Dandy criteria. There was a significant improvement in the Humphrey 24-2 mean deviation (MD) in the study eyes (worse affected eye at presentation) in both the medically treated group (+2.0 dB; from -5.60 dB at baseline to -3.60 dB at final follow-up, p < .01) and in the fellow eyes in the medically treated group (+1.70 dB, from -4.40 dB at baseline to -2.74 dB at final follow-up, p < .01). Higher papilloedema grade (beta -0.66, p < .001) and age (p < .02) were inversely correlated with the final visual field MD in the study eye. The visual outcome for the IIH patients in our study was predominantly favourable, but patients with high-grade papilloedema had a worse visual prognosis and required more aggressive treatment.
© 2021 Taylor & Francis Group, LLC.

Entities:  

Keywords:  Idiopathic intracranial hypertension; Pseudotumor cerebri; visual outcome

Year:  2021        PMID: 35273409      PMCID: PMC8903789          DOI: 10.1080/01658107.2021.1984540

Source DB:  PubMed          Journal:  Neuroophthalmology        ISSN: 0165-8107


  17 in total

Review 1.  Idiopathic intracranial hypertension in the Middle East: A growing concern.

Authors:  Sumayya J Almarzouqi; Michael L Morgan; Andrew G Lee
Journal:  Saudi J Ophthalmol       Date:  2014-09-28

2.  Intracranial idiopathic hypertension: 1-year follow-up study.

Authors:  D D'Amico; M Curone; A Erbetta; G Farago'; S Bianchi-Marzoli; P Ciasca; G Bussone; L Chiapparini
Journal:  Neurol Sci       Date:  2014-05       Impact factor: 3.307

3.  Revised diagnostic criteria for the pseudotumor cerebri syndrome in adults and children.

Authors:  Deborah I Friedman; Grant T Liu; Kathleen B Digre
Journal:  Neurology       Date:  2013-08-21       Impact factor: 9.910

4.  The idiopathic intracranial hypertension treatment trial: design considerations and methods.

Authors:  Deborah I Friedman; Michael P McDermott; Karl Kieburtz; Mark Kupersmith; Ann Stoutenburg; John L Keltner; Steven E Feldon; Eleanor Schron; James J Corbett; Michael Wall
Journal:  J Neuroophthalmol       Date:  2014-06       Impact factor: 3.042

5.  Risk factors for poor visual outcome in patients with idiopathic intracranial hypertension.

Authors:  Michael Wall; Julie Falardeau; William A Fletcher; Robert J Granadier; Byron L Lam; Reid A Longmuir; Anil D Patel; Beau B Bruce; Hua He; Michael P McDermott
Journal:  Neurology       Date:  2015-08-05       Impact factor: 9.910

6.  Factors affecting visual loss in benign intracranial hypertension.

Authors:  J C Orcutt; N G Page; M D Sanders
Journal:  Ophthalmology       Date:  1984-11       Impact factor: 12.079

7.  Clinical and Neuro-ophthalmologic Predictors of Visual Outcome in Idiopathic Intracranial Hypertension.

Authors:  Aastha Takkar; Manoj Kumar Goyal; Reema Bansal; Vivek Lal
Journal:  Neuroophthalmology       Date:  2018-01-09

8.  The incidence of idiopathic intracranial hypertension in Israel from 2005 to 2007: results of a nationwide survey.

Authors:  A Kesler; N Stolovic; Y Bluednikov; T Shohat
Journal:  Eur J Neurol       Date:  2014-04-02       Impact factor: 6.089

9.  Pseudotumor cerebri in men.

Authors:  K B Digre; J J Corbett
Journal:  Arch Neurol       Date:  1988-08

Review 10.  A review of adult obesity prevalence, trends, risk factors, and epidemiologic methods in Kuwait.

Authors:  Stalo Karageorgi; Osama Alsmadi; Kazem Behbehani
Journal:  J Obes       Date:  2013-12-17
View more
  1 in total

1.  The idiopathic intracranial hypertension prospective cohort study: evaluation of prognostic factors and outcomes.

Authors:  Mark Thaller; Victoria Homer; Yousef Hyder; Andreas Yiangou; Anthony Liczkowski; Anthony W Fong; Jasvir Virdee; Rachel Piccus; Marianne Roque; Susan P Mollan; Alexandra J Sinclair
Journal:  J Neurol       Date:  2022-10-15       Impact factor: 6.682

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.